Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600127 | 0.89 | SLC5A2 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL2600143 | 0.89 | SLC5A2 (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2600121 | 0.86 | SLC5A2 (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2600124 | 0.85 | SLC5A2 (0.41) | SLC5A2SLC5A1 | |
| SCHEMBL2600120 | 0.85 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL15627071 | 0.85 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2130587 | 0.85 | BCHE (0.37) | SLC5A2 | |
| SCHEMBL15627069 | 0.83 | SLC5A2 (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14850074 | 0.83 | SLC5A2 (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2600150 | 0.81 | SLC5A2 (0.38) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101051-A1 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.